Innocan Pharma Corp
CNSX:INNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AP Rentals Holdings Ltd
HKEX:1496
|
HK |
|
Z
|
Zhejiang Wanfeng Chemical Co Ltd
SSE:603172
|
CN |
|
Telefonaktiebolaget LM Ericsson
STO:ERIC B
|
SE |
|
T
|
THK Co Ltd
TSE:6481
|
JP |
|
Kinepolis Group NV
XBRU:KIN
|
BE |
|
L
|
Le Lavoir Ltd
BSE:539814
|
IN |
|
Bharat Bijlee Ltd
BSE:503960
|
IN |
|
Coventry Group Ltd
ASX:CYG
|
AU |
|
Valid Solucoes SA
BOVESPA:VLID3
|
BR |
|
Wuxi Hyatech Co Ltd
SSE:688510
|
CN |
|
P
|
Petrolimex Joint Stock Tanker Co
VN:PJT
|
VN |
|
Z
|
Zhejiang Zomax Transmission Co Ltd
SSE:603767
|
CN |
Innocan Pharma Corp
Inventory
Innocan Pharma Corp
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
Inventory
$2.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Inventory
$3.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Inventory
$4.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Inventory
$113k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
Inventory
₪550k
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
See Also
What is Innocan Pharma Corp's Inventory?
Inventory
2.2m
USD
Based on the financial report for Dec 31, 2025, Innocan Pharma Corp's Inventory amounts to 2.2m USD.
What is Innocan Pharma Corp's Inventory growth rate?
Inventory CAGR 5Y
38%
Over the last year, the Inventory growth was -34%. The average annual Inventory growth rates for Innocan Pharma Corp have been 24% over the past three years , 38% over the past five years .
